Analysis of platelet α2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy

Bernát János Béres, E. Tóth-Zsámboki, Katarína Vargová, Ádám László, T. Masszi, Gábor Kerecsen, I. Préda, R. Kiss

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Combined antiplatelet therapy reduces recurrent atherothrombotic events in stable coronary disease patients; however, high residual platelet reactivity measured ex vivo still raises concerns as a condition related to treatment failure. Alpha-2 adrenoceptor enhances platelet reactivity and might contribute to this phenomenon. For the present study, 121 stable angina patients on standard dual antiplatelet therapy (75 mg clopidogrel and 100 mg acetylsalicylic acid) were recruited. Born aggregometry was performed with adenosine diphosphate (ADP), collagen and epinephrine. To verify platelet adrenergic activity, potentiation by low-dose epinephrine and inhibition by selective alpha-2 receptor blocker atipamezole were determined. To assess the P2Y 12-specific residual activity, cangrelor was used. Plasma no-repinephrine, soluble CD40-ligand, high-sensitivity-C-reactive protein (hsCRP) - and in 24 subjects platelet P-selectin positivity were measured. Epinephrine - at very low concentration (10-9g/ml) - significantly potentiates (1.25 μM ADP: 26.5% vs. 43%; 5 μM ADP: 53% vs. 64.5%; collagen: 17% vs 42%, p12 activity as well. HsCRP and soluble CD40-ligand levels were similar. In conclusion, stable coronary heart disease patients with prominent adrenoceptor activity in vitro have significantly increased platelet aggregability and more functional P2Y 12 receptor, indicating poor inhibitory response to thienopyridines. Therefore, platelet adrenergic receptor represents a considerable, dynamic factor of high residual platelet reactivity and might contribute to cardiovascular events indicating failure of antiplatelet therapy.

Original languageEnglish
Pages (from-to)829-836
Number of pages8
JournalThrombosis and Haemostasis
Volume100
Issue number5
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Adrenergic Receptors
Coronary Artery Disease
Blood Platelets
Adenosine Diphosphate
Epinephrine
CD40 Ligand
clopidogrel
Therapeutics
Coronary Disease
Collagen
Thienopyridines
P-Selectin
Stable Angina
Treatment Failure
Adrenergic Agents
C-Reactive Protein
Aspirin

Keywords

  • Antiplatelet agents
  • Cardiology
  • Platelet physiology
  • Receptors

ASJC Scopus subject areas

  • Hematology

Cite this

Analysis of platelet α2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. / Béres, Bernát János; Tóth-Zsámboki, E.; Vargová, Katarína; László, Ádám; Masszi, T.; Kerecsen, Gábor; Préda, I.; Kiss, R.

In: Thrombosis and Haemostasis, Vol. 100, No. 5, 11.2008, p. 829-836.

Research output: Contribution to journalArticle

@article{1f580709d0e0441b922e3f137b904a6d,
title = "Analysis of platelet α2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy",
abstract = "Combined antiplatelet therapy reduces recurrent atherothrombotic events in stable coronary disease patients; however, high residual platelet reactivity measured ex vivo still raises concerns as a condition related to treatment failure. Alpha-2 adrenoceptor enhances platelet reactivity and might contribute to this phenomenon. For the present study, 121 stable angina patients on standard dual antiplatelet therapy (75 mg clopidogrel and 100 mg acetylsalicylic acid) were recruited. Born aggregometry was performed with adenosine diphosphate (ADP), collagen and epinephrine. To verify platelet adrenergic activity, potentiation by low-dose epinephrine and inhibition by selective alpha-2 receptor blocker atipamezole were determined. To assess the P2Y 12-specific residual activity, cangrelor was used. Plasma no-repinephrine, soluble CD40-ligand, high-sensitivity-C-reactive protein (hsCRP) - and in 24 subjects platelet P-selectin positivity were measured. Epinephrine - at very low concentration (10-9g/ml) - significantly potentiates (1.25 μM ADP: 26.5{\%} vs. 43{\%}; 5 μM ADP: 53{\%} vs. 64.5{\%}; collagen: 17{\%} vs 42{\%}, p12 activity as well. HsCRP and soluble CD40-ligand levels were similar. In conclusion, stable coronary heart disease patients with prominent adrenoceptor activity in vitro have significantly increased platelet aggregability and more functional P2Y 12 receptor, indicating poor inhibitory response to thienopyridines. Therefore, platelet adrenergic receptor represents a considerable, dynamic factor of high residual platelet reactivity and might contribute to cardiovascular events indicating failure of antiplatelet therapy.",
keywords = "Antiplatelet agents, Cardiology, Platelet physiology, Receptors",
author = "B{\'e}res, {Bern{\'a}t J{\'a}nos} and E. T{\'o}th-Zs{\'a}mboki and Katar{\'i}na Vargov{\'a} and {\'A}d{\'a}m L{\'a}szl{\'o} and T. Masszi and G{\'a}bor Kerecsen and I. Pr{\'e}da and R. Kiss",
year = "2008",
month = "11",
doi = "10.1160/TH08-03-0158",
language = "English",
volume = "100",
pages = "829--836",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "5",

}

TY - JOUR

T1 - Analysis of platelet α2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy

AU - Béres, Bernát János

AU - Tóth-Zsámboki, E.

AU - Vargová, Katarína

AU - László, Ádám

AU - Masszi, T.

AU - Kerecsen, Gábor

AU - Préda, I.

AU - Kiss, R.

PY - 2008/11

Y1 - 2008/11

N2 - Combined antiplatelet therapy reduces recurrent atherothrombotic events in stable coronary disease patients; however, high residual platelet reactivity measured ex vivo still raises concerns as a condition related to treatment failure. Alpha-2 adrenoceptor enhances platelet reactivity and might contribute to this phenomenon. For the present study, 121 stable angina patients on standard dual antiplatelet therapy (75 mg clopidogrel and 100 mg acetylsalicylic acid) were recruited. Born aggregometry was performed with adenosine diphosphate (ADP), collagen and epinephrine. To verify platelet adrenergic activity, potentiation by low-dose epinephrine and inhibition by selective alpha-2 receptor blocker atipamezole were determined. To assess the P2Y 12-specific residual activity, cangrelor was used. Plasma no-repinephrine, soluble CD40-ligand, high-sensitivity-C-reactive protein (hsCRP) - and in 24 subjects platelet P-selectin positivity were measured. Epinephrine - at very low concentration (10-9g/ml) - significantly potentiates (1.25 μM ADP: 26.5% vs. 43%; 5 μM ADP: 53% vs. 64.5%; collagen: 17% vs 42%, p12 activity as well. HsCRP and soluble CD40-ligand levels were similar. In conclusion, stable coronary heart disease patients with prominent adrenoceptor activity in vitro have significantly increased platelet aggregability and more functional P2Y 12 receptor, indicating poor inhibitory response to thienopyridines. Therefore, platelet adrenergic receptor represents a considerable, dynamic factor of high residual platelet reactivity and might contribute to cardiovascular events indicating failure of antiplatelet therapy.

AB - Combined antiplatelet therapy reduces recurrent atherothrombotic events in stable coronary disease patients; however, high residual platelet reactivity measured ex vivo still raises concerns as a condition related to treatment failure. Alpha-2 adrenoceptor enhances platelet reactivity and might contribute to this phenomenon. For the present study, 121 stable angina patients on standard dual antiplatelet therapy (75 mg clopidogrel and 100 mg acetylsalicylic acid) were recruited. Born aggregometry was performed with adenosine diphosphate (ADP), collagen and epinephrine. To verify platelet adrenergic activity, potentiation by low-dose epinephrine and inhibition by selective alpha-2 receptor blocker atipamezole were determined. To assess the P2Y 12-specific residual activity, cangrelor was used. Plasma no-repinephrine, soluble CD40-ligand, high-sensitivity-C-reactive protein (hsCRP) - and in 24 subjects platelet P-selectin positivity were measured. Epinephrine - at very low concentration (10-9g/ml) - significantly potentiates (1.25 μM ADP: 26.5% vs. 43%; 5 μM ADP: 53% vs. 64.5%; collagen: 17% vs 42%, p12 activity as well. HsCRP and soluble CD40-ligand levels were similar. In conclusion, stable coronary heart disease patients with prominent adrenoceptor activity in vitro have significantly increased platelet aggregability and more functional P2Y 12 receptor, indicating poor inhibitory response to thienopyridines. Therefore, platelet adrenergic receptor represents a considerable, dynamic factor of high residual platelet reactivity and might contribute to cardiovascular events indicating failure of antiplatelet therapy.

KW - Antiplatelet agents

KW - Cardiology

KW - Platelet physiology

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=55549117844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55549117844&partnerID=8YFLogxK

U2 - 10.1160/TH08-03-0158

DO - 10.1160/TH08-03-0158

M3 - Article

VL - 100

SP - 829

EP - 836

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 5

ER -